We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
TTI-622 and TTI-621 are the only CD47-targeted molecules to show meaningful monotherapy activity and complete responses across multiple hematological malignancies, the companies said. Read More
Eli Lilly’s biologics division, Lilly Bio-Medicines, is splitting into two distinct units, one of which will focus entirely on approved and phase 3 drugs for pain and neurodegeneration — including Alzheimer’s disease. Read More
There’s no national shortage of the life-saving opiate antagonist naloxone — just a shortage of the free or cheap single-use vials that Pfizer has distributed by the millions since 2017. Read More
Pfizer has announced that it will transfer the rights for Phospholine Iodide (echothiophate iodide), a treatment for a rare type of glaucoma, to New York-based biotech Fera Pharmaceuticals to ensure a continued supply of the decades-old drug that the company stopped distributing in May. Read More
The Institute for Clinical and Economic Review (ICER) issued its final word on Biogen’s newly approved and very controversial $56,000-a-year Alzheimer’s drug Aduhelm (aducanumab) Thursday, and that word is “no.” Read More
In a late-stage trial, the vaccine proved to be 100 percent effective in preventing moderate and severe disease, and more than 90 percent effective at preventing symptomatic infections. Read More